Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216495 · ClinicalTrials.gov registry record · NA
Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
A NA study of Aerobic Exercise and Early Stage Triple Negative Breast Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT07216495: Recruiting NA study of Aerobic Exercise and Early Stage Triple Negative Breast Cancer, sponsored by M.D. Anderson Cancer Center.
NCT07216495 is a NA study of Aerobic Exercise and Early Stage Triple Negative Breast Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 141-participant average among 3 other Aerobic Exercise trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216495, a NA study of Aerobic Exercise and Early Stage Triple Negative Breast Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.
Primary Outcome
Feasibility will be measured by adherence to both exercise frequency and time (duration/intensity) at the supervised sessions.
Conditions Studied
Interventions
- OTHER Exercise
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2030-10-30 |
| Phase | NA |
What NCT07216495 shows while recruiting
NCT07216495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 141-participant average among 3 other Aerobic Exercise trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Aerobic Exercise appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.
NCT07216495 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07216495 about?
NCT07216495 is a clinical study titled "Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC". To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.
What is the current status of trial NCT07216495?
This trial is currently recruiting. It is a NA study. The enrollment target is 33 participants. The study started on 2026-02-23. Estimated completion is 2030-10-30.
What conditions does trial NCT07216495 study?
This clinical trial studies the following conditions: Aerobic Exercise, Early Stage Triple Negative Breast Cancer.
What interventions are being tested in trial NCT07216495?
The interventions under investigation include: Exercise (OTHER).
Who is sponsoring clinical trial NCT07216495?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216495 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aerobic Exercise
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI